Compare Mesoblast Limited (MESO) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Mesoblast Limited trades at $16.28 (market cap $2.17B), while iShares 10 20 Year Treasury Bond ETF trades at $97.83. The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MESO | TLH | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Fixed Income |
52-Week High | $20.96 | $105.36 |
52-Week Low | $12.88 | $97.13 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
TLH trades at $98.13, down 0.56% today amid a bearish technical signal. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Recent dividends of $0.41 and $0.36 for H1-26 and H2-26 signal shareholder returns, but key valuation and profitability ratios are unavailable, limiting fundamental clarity.
The outlook is cautious due to bearish technicals and lack of financial metrics. Risks include market volatility from geopolitical tensions and Fed policy uncertainty. Investors need updated earnings and guidance to assess growth potential amid macroeconomic headwinds highlighted in recent financial news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
